Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.

BACKGROUND Localized recurrent prostate cancer after primary radiotherapy can be curatively treated using salvage iodine-125 ((125)I) brachytherapy. Selection is hampered by a lack of predictive factors for cancer control. This study aims to develop and internally validate a prognostic model for biochemical failure (BF) after salvage (125)I brachytherapy. METHODS AND MATERIALS Whole-gland salvage (125)I brachytherapy patients were treated between 1993 and 2010 in two radiotherapy centers in the Netherlands. Multivariable Cox regression was performed to assess the predictive value of clinical parameters related to BF (Phoenix-definition [prostate-specific antigen [PSA]-nadir + 2.0 ng/mL]). Missing data were handled by multiple imputation. The model's discriminatory ability was assessed with Harrell's C-statistic. Internal validation was performed using bootstrap resampling (2000 data sets). Goodness-of-fit was evaluated with calibration plots. All analyses were performed using the recently published TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) statement. RESULTS After median followup of 74 months (range 5-138), 43 of a total 62 patients developed BF. In multivariable analysis, disease-free survival interval (DFSI) after primary therapy and pre-salvage prostate-specific antigen doubling time (PSADT) were predictors of BF: corrected hazard ratio (HR) 0.99 (95% confidence interval 0.97-0.999; p = 0.04) and 0.94 (95% confidence interval 0.89-0.99; p = 0.03), both for a 1-month increase (optimism-adjusted C-statistic 0.70). Calibration was accurate up to 36 months. Of patients with PSADT >30 months and DFSI >60 months, 36-month biochemical disease-free survival was >75%. Every 12-month increase in DFSI will allow 3-month decrease in PSADT while maintaining the same biochemical recurrence-free rates. CONCLUSIONS We have presented results from a cohort of patients undergoing salvage (125)I-brachytherapy. Our data show that better selection of patients is possible with the DFSI and PSADT.

[1]  H. G. van der Poel,et al.  Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. , 2011, European urology.

[2]  A. Evans,et al.  MR-guided prostate biopsy for planning of focal salvage after radiation therapy. , 2015, Radiology.

[3]  G. Perry,et al.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.

[4]  Ming-Hui Chen,et al.  Magnetic resonance image‐guided salvage brachytherapy after radiation in select men who initially presented with favorable‐risk prostate cancer , 2007, Cancer.

[5]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[6]  M. Roach,et al.  Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? , 2014, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[7]  Scott O. Quarrier,et al.  Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. , 2013, European urology.

[8]  M. Regan,et al.  Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. , 2011, The Journal of urology.

[9]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[10]  P. Unger,et al.  Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[11]  Y. Yamada,et al.  Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. , 2011, European urology.

[12]  J. Cesaretti,et al.  Salvage brachytherapy for recurrent prostate cancer. , 2014, Brachytherapy.

[13]  Theo Stijnen,et al.  Using the outcome for imputation of missing predictor values was preferred. , 2006, Journal of clinical epidemiology.

[14]  H. G. van der Poel,et al.  Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. , 2010, Brachytherapy.

[15]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[16]  A. D'Amico,et al.  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.

[17]  I. Hsu,et al.  Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[18]  A. D'Amico,et al.  Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Yamada,et al.  A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy , 2013, Brachytherapy.

[20]  D. Beyer.  Brachytherapy for recurrent prostate cancer after radiation therapy. , 2003, Seminars in radiation oncology.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity , 2014, Radiation oncology.

[23]  Stephen J Ramey,et al.  Re-irradiation for salvage of prostate cancer failures after primary radiotherapy , 2013, World Journal of Urology.

[24]  M. Moerland,et al.  Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Y. Yamada,et al.  The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. , 2015, European urology.

[26]  G. Swanson,et al.  Salvage brachytherapy for localized prostate cancer after radiotherapy failure. , 1999, Urology.

[27]  I. Hsu,et al.  Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. , 2013, International journal of radiation oncology, biology, physics.

[28]  U. Grouven,et al.  Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. , 2011, European urology.

[29]  S. Love,et al.  Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.

[30]  S. Crouzet,et al.  Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.